Dashboard
Manage Tickers

PRLD Prelude Therapeutics Inc

Nasdaq preludetx.com


$ 1.53 $ -0.08 (-5.06 %)    

Thursday, 23-Oct-2025 17:30:43 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 611.61 $ 5.09 (0.84 %)
DIA $ 467.15 $ 1.51 (0.32 %)
SPY $ 672.24 $ 3.96 (0.59 %)
TLT $ 91.36 $ -0.63 (-0.68 %)
GLD $ 378.46 $ 1.51 (0.4 %)
$ 1.5
$ 1.54
$ 1.45 x 500
$ 1.59 x 88
$ 1.47 - $ 1.59
$ 0.61 - $ 1.91
113,781
na
84.9M
$ 1.18
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-06-2025 03-31-2025 10-Q
3 03-10-2025 12-31-2024 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 02-15-2024 12-31-2023 10-K
8 11-01-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-08-2023 03-31-2023 10-Q
11 03-15-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 03-17-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-11-2021 03-31-2021 10-Q
19 03-16-2021 12-31-2020 10-K
20 11-10-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

prelude-therapeutics-granted-us-patent--us-12448389-b2-for-brm-targeting-compounds-and-associated-methods-of-use
Prelude Therapeutics Granted U.S. Patent #...
10/21/2025 20:00:30

https://ppubs.uspto.gov/api/pdf/downloadPdf/12448389?requestToken=eyJzdWIiOiJlZWQ3ZTE2MS1kZjI1LTQyNTktODVjNy02NmE4NGMzYWM1ZDciL...

hc-wainwright--co-reiterates-buy-on-prelude-therapeutics-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on Prel...
09/23/2025 11:08:35

HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $5 price...

jmp-securities-maintains-market-outperform-on-prelude-therapeutics-lowers-price-target-to-3
JMP Securities Maintains Market Outperform...
08/18/2025 14:37:02

JMP Securities analyst Reni J. Benjamin maintains Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperform and lowers the...

prelude-therapeutics-q2-eps-041-beats-044-estimate-current-cash-runway-into-q2-of-2026-with-773m-in-cash-cash-equivalents-restricted-cash-and-marketable-securities
Prelude Therapeutics Q2 EPS $(0.41) Beats ...
08/14/2025 11:18:51

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
05/27/2025 21:06:12

prelude-therapeutics-q1-eps-042-beats-047-estimate
Prelude Therapeutics Q1 EPS $(0.42) Beats ...
05/06/2025 20:36:35

Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of ...

hc-wainwright--co-reiterates-buy-on-prelude-therapeutics-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on Prel...
05/05/2025 10:44:26

HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $5 price...

jmp-securities-reiterates-market-outperform-on-prelude-therapeutics-maintains-4-price-target
JMP Securities Reiterates Market Outperfor...
04/29/2025 16:36:21

JMP Securities analyst Reni Benjamin reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperform and maintains $4...

hc-wainwright--co-reiterates-buy-on-prelude-therapeutics-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on Prel...
04/08/2025 11:24:22

HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $5 price...

12-health-care-stocks-moving-in-fridays-intraday-session
12 Health Care Stocks Moving In Friday's I...
03/28/2025 17:05:40

12-health-care-stocks-moving-in-fridays-pre-market-session
12 Health Care Stocks Moving In Friday's P...
03/28/2025 12:05:48

12-health-care-stocks-moving-in-thursdays-after-market-session
12 Health Care Stocks Moving In Thursday's...
03/27/2025 21:05:49

12-health-care-stocks-moving-in-fridays-after-market-session
12 Health Care Stocks Moving In Friday's A...
03/14/2025 21:05:49

citizens-capital-markets-reiterates-market-outperform-on-prelude-therapeutics-maintains-4-price-target
Citizens Capital Markets Reiterates Market...
03/12/2025 15:04:33

Citizens Capital Markets analyst Reni Benjamin reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperform and ma...

prelude-therapeutics-fy-sales-7000m-beat-2000m-estimate
Prelude Therapeutics FY Sales $7.000M Beat...
03/10/2025 11:46:10

Prelude Therapeutics (NASDAQ:PRLD) reported quarterly sales of $7.000 million which beat the analyst consensus estimate of $2.0...

12-health-care-stocks-moving-in-tuesdays-pre-market-session
12 Health Care Stocks Moving In Tuesday's ...
02/11/2025 12:05:38

why-lattice-semiconductor-shares-are-trading-higher-by-around-15-here-are-20-stocks-moving-premarket
Why Lattice Semiconductor Shares Are Tradi...
02/11/2025 10:53:31

prelude-therapeutics-named-bryant-d-lim-as-permanent-cfo
Prelude Therapeutics Named Bryant D. Lim A...
02/05/2025 21:30:52

jmp-securities-reiterates-market-outperform-on-prelude-therapeutics-lowers-price-target-to-4
JMP Securities Reiterates Market Outperfor...
12/11/2024 17:24:12

JMP Securities analyst Reni Benjamin reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperform and lowers the p...

prelude-therapeutics-announced-the-presentation-of-the-first-interim-clinical-data-from-its-ongoing-open-label-dose-escalation-trial-of-prt2527-a-potent-and-highly-selective-cdk9-inhibitor-as-monotherapy-and-in-combination-with-zanubrutinib-in-patients-with-relapsedrefractory-lymphoid-malignancies
Prelude Therapeutics Announced The Present...
12/11/2024 12:39:08

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION